Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. Brand TM, et al. Among authors: saloura v. Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12. Clin Cancer Res. 2015. PMID: 25767293 Free PMC article.
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. Taylor RJ, et al. Among authors: saloura v. Cancer Immunol Res. 2015 May;3(5):567-74. doi: 10.1158/2326-6066.CIR-14-0188. Epub 2015 Mar 13. Cancer Immunol Res. 2015. PMID: 25769300 Free PMC article. Clinical Trial.
Immune profiles in primary squamous cell carcinoma of the head and neck.
Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I, Zhavoronkov A, Sidransky D, Bedi A, Hoque MO, Koeppen H, Keck MK, Khattri A, London N, Kotlov N, Fatima A, Vougiouklakis T, Nakamura Y, Lingen M, Agrawal N, Savage PA, Kron S, Kline J, Kowanetz M, Seiwert TY. Saloura V, et al. Oral Oncol. 2019 Sep;96:77-88. doi: 10.1016/j.oraloncology.2019.06.032. Epub 2019 Jul 12. Oral Oncol. 2019. PMID: 31422218 Free PMC article.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. Rosenberg AJ, et al. Among authors: saloura v. Ann Oncol. 2023 Aug;34(8):714-722. doi: 10.1016/j.annonc.2023.05.002. Epub 2023 May 13. Ann Oncol. 2023. PMID: 37182801 Clinical Trial.
EGFR-based bioradiotherapy in SCCHN.
Saloura V, Vokes EE. Saloura V, et al. Lancet Oncol. 2015 Feb;16(2):129-30. doi: 10.1016/S1470-2045(15)70006-9. Epub 2015 Jan 15. Lancet Oncol. 2015. PMID: 25596658 No abstract available.
47 results